Interview with Marcin Hanczaruk, General Manager, Ferring Pharmaceuticals Poland
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Address: ul. Bonifraterska 17
00-203 Warszawa
Poland
Tel: +48 22 246 0680
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
“We have made some progress in terms of the conceptualization of depression as a disease. Previously, the popular attitude was that depression was a temporary emotion; one that could be…
IMS’ General Manager, Maciej Kuzmierkiewicz, discusses the effects of the Reimbursement Act—the new legislative framework implemented in January 2012—which completely reshaped the rules of the game for the Polish pharmaceutical sector…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been heading the affiliate since its creation in 1997; therefore you saw its evolution and growth. Would you say that Apotex Poland has evolved in accordance with the…
You have been quite recently appointed at the head of the Polish affiliate of AstraZeneca. With which personal ambitions did you come and what was the mission you were given…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable. The market size is over 5 billion Euros which makes Poland the 6th biggest market…
You were appointed general manager of Astellas Poland in early 2006, only a bit after Astellas Pharma Inc. was established, on April 1, 2005 through the merger of the mother…
BAUSCH + LOMB has over 150 years of heritage and has always been associated with optics and ophthalmology. Therefore the company has been able to build a very strong brand…
Given Cegedim’s global reach and your 13 year experience of operating as a consultant to the Polish pharma industry, how would you describe the market to the international readers of…
As Squibb Corporation and Bristol-Myers merged in 1989, Bristol-Myers Squibb has been officially operating in this market since that date, but the affiliate has a long history previous to that.…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
See our Cookie Privacy Policy Here